Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solut...( COLUMBUS Ohio July 29 /- ...),Health

COLUMBUS, Ohio, July 29 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by the U.S. Food and Drug Administration. The product is available in 30mL bottles for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Risperidone Oral Solution, 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. Annual sales of Risperidone Oral Solution, 1mg/mL are approximately $69.6 Million(1).

Full prescribing information for Risperidone Oral Solution, 1mg/mL is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical comp
'/>"/>